Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Assessing Photoreceptor Structure in Retinitis Pigmentosa and Usher Syndrome.

Sun LW, Johnson RD, Langlo CS, Cooper RF, Razeen MM, Russillo MC, Dubra A, Connor TB Jr, Han DP, Pennesi ME, Kay CN, Weinberg DV, Stepien KE, Carroll J.

Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2428-42. doi: 10.1167/iovs.15-18246.

2.

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F.

Oncotarget. 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480.

3.

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.

Fabi A, Moscetti L, Ciccarese M, Caramanti M, Salesi N, La Verde N, Russillo M, Generali D, Scandurra G, Vari S, Pacetti U, Cognetti F, Giannarelli D.

Future Oncol. 2015;11(3):431-8. doi: 10.2217/fon.14.271.

PMID:
25675124
4.

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F.

BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482.

5.

Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?

Russillo M, Di Benedetto A, Metro G, Ferretti G, Papaldo P, Cognetti F, Mottolese M, Fabi A.

J Clin Oncol. 2011 Jul 10;29(20):2834-5; author reply 2835. doi: 10.1200/JCO.2011.35.1742. No abstract available.

PMID:
21670454
6.

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.

Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nisticò C, Russillo M, Papaldo P, Ferretti G, Aapro M, Giannarelli D, Cognetti F.

J Exp Clin Cancer Res. 2011 May 12;30:54. doi: 10.1186/1756-9966-30-54.

7.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J.

Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626.

8.

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center.

Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, Moscetti L, Russillo M, Lanzetta G, Mansueto G, Pace A, Maschio M, Vidiri A, Sperduti I, Cognetti F, Carapella CM.

J Exp Clin Cancer Res. 2011 Jan 18;30:10. doi: 10.1186/1756-9966-30-10.

9.

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, Crinò L, Papaldo P, Mottolese M, Cognetti F, Fabi A, Gori S.

Ann Oncol. 2011 Mar;22(3):625-30. doi: 10.1093/annonc/mdq434.

PMID:
20724575
10.

Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.

Fabi A, Metro G, Vidiri A, Lanzetta G, Carosi M, Telera S, Maschio M, Russillo M, Sperduti I, Carapella CM, Cognetti F, Pace A.

J Neurooncol. 2010 Nov;100(2):209-15. doi: 10.1007/s11060-010-0163-3.

PMID:
20352471
11.

Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.

Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM.

Cancer Chemother Pharmacol. 2010 Jan;65(2):391-7. doi: 10.1007/s00280-009-1155-x.

PMID:
19847425
12.

Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.

Fabi A, Russillo M, Metro G, Vidiri A, Di Giovanni S, Cognetti F.

Anticancer Res. 2009 Jul;29(7):2607-10.

13.

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.

Fabi A, Metro G, Russillo M, Vidiri A, Carapella CM, Maschio M, Cognetti F, Jandolo B, Mirri MA, Sperduti I, Telera S, Carosi M, Pace A.

BMC Cancer. 2009 Mar 31;9:101. doi: 10.1186/1471-2407-9-101.

14.

Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.

Metro G, Fabi A, Russillo M, Papaldo P, De Laurentiis M, Ferretti G, Pellegrini D, Nuzzo C, Graziano V, Vici P, Introna M, Felici A, Cognetti F, Carlini P.

Anticancer Res. 2008 Mar-Apr;28(2B):1245-58. Review.

15.

Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study.

Fabi A, Ciccarese M, Metro G, Savarese A, Giannarelli D, Nuzzo CM, Russillo M, Sperduti I, Carbone I, Bria E, Cognetti F.

Support Care Cancer. 2008 Dec;16(12):1375-80. doi: 10.1007/s00520-008-0438-9.

PMID:
18478278
16.

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.

Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F.

Breast. 2008 Oct;17(5):499-505. doi: 10.1016/j.breast.2008.03.006. Review.

PMID:
18450443
17.

Male breast cancer: 6-year experience.

La Pinta M, Fabi A, Ascarelli A, Ponzani T, Di Carlo V, Scicchitano F, Saputo S, Russillo M, Andrich R.

Minerva Chir. 2008 Apr;63(2):71-8. English, Italian.

PMID:
18427439
18.

[Aromatase inhibitors in advanced breast cancer].

Spinelli GP, Tomao F, Miele E, Pasciuti G, Russillo M, Tomao S.

Recenti Prog Med. 2008 Jan;99(1):34-8. Review. Italian.

PMID:
18389871
19.

Bone of the hands as unusual metastastatic site of renal cell carcinoma.

Salesi N, Russillo M, Marandino F, Ruggeri EM, Metro G, Cognetti F, Fabi A.

J Exp Clin Cancer Res. 2007 Dec;26(4):595-7.

PMID:
18365558
20.

Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.

Metro G, Sperduti I, Russillo M, Milella M, Cognetti F, Fabi A.

Oncologist. 2007 Dec;12(12):1467-9; author reply 1469-71. doi: 10.1634/theoncologist.12-12-1467. No abstract available.

Items per page

Supplemental Content

Loading ...
Support Center